Oncolytics Biotech, Inc.

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Oncolytics Biotech reports strong earnings and growth opportunities ahead

Oncolytics Biotech's Q4 2022 earnings call highlighted notable progress, strong financials, and promising trial outcomes.
The company faces challenges in trial design and collaboration agreements but is well-positioned for growth.
Opportunities lie in upcoming trial readouts, business development efforts, and expansion into Asian markets.

Oncolytics Biotech progresses in key trials, eyes market impact

Oncolytics Biotech, Inc. demonstrated progress in key trials and financial stability, positioning itself for potential market impact.
Strategic focus on validating data, understanding mechanisms of action, and pursuing efficient registration pathways underscores the company's commitment to innovation.
Challenges in managing trial outcomes and sustaining growth require careful navigation, but opportunities in diversification and market expansion offer avenues for success.
Overall, the company's emphasis on strategic milestones and licensing opportunities signals a proactive approach to maximizing value and market potential.

Oncolytics Biotech reports positive Q2 results and eyes growth opportunities

Oncolytics Biotech's Q2 2023 earnings call highlighted positive progress in clinical trials and strong financial performance.
The company's focus on research and development, business development efforts, and commitment to expansion present growth opportunities.
Challenges include trial execution concerns, complexities in combining treatments, and regulatory pathways that need to be navigated.

Oncolytics Biotech reports positive Q3 results and eyes strategic partnerships

Oncolytics Biotech demonstrated strong performance and promising outcomes in Q3 2023, with pela showing success in clinical trials for pancreatic and colorectal cancers.
While facing challenges in data clarity and market positioning, the company has opportunities to expand treatments, collaborations, and advance regulatory studies.
Overall, the company's financial stability, clinical progress, and strategic partnerships position it well for future growth and advancements in cancer treatments.

Oncolytics Biotech reports robust earnings, eyes oncology expansion in 2024

Oncolytics Biotech, Inc. showcased strong financial performance and progress in becoming a late-stage cancer company.
While facing challenges in research validation and managing operating costs, the company is well-positioned for growth.
Opportunities lie in validating survival benefits, expanding pela's market potential, and advancing strategic objectives in oncology.
Overall, Oncolytics' focus on innovation, financial prudence, and clinical advancements sets a positive trajectory for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO  and CALGARY, AB , Dec. 18, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the presentation of two data sets through two abstracts showcasing pelareorep's potential in difficult-to-treat gastrointestinal cancers were accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco January 23-25, 2025. Tom Heineman, M.D.

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without atezolizumab The study will begin with 30 patients, with an option to expand to an additional 34 participants SAN DIEGO and CALGARY, AB , Dec. 3, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that the Data Safety Monitoring Board (DSMB) has recommended continued enrollment in Cohort 5 of the GOBLET study following their review of initial safety data. Enrollment in this cohort will resume pending final approval from the Paul Ehrlich Institute (PEI), Germany's medical regulatory body.

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

Oncolytics Biotech Inc. (ONCY) Q3 2024 Earnings Call Transcript

BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study Upcoming GOBLET milestones include updated efficacy data from anal cancer cohort and safety run-in data from the modified FOLFIRINOX pancreatic cancer cohort Cash position of $19.6 million as of September 30, 2024 Management hosting conference call and webcast today at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Nov. 12, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced third quarter financial results and operational highlights.

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

Conference call and webcast to take place on Tuesday, November 12, 2024, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Nov. 11, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Tuesday, November 12, 2024, at 8:30 a.m.

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

Oncolytics stock soars as the company seeks an accelerated approval pathway for its lead candidate, pelareorep, to treat a breast cancer indication.

ONCY Stock Up on Regulatory Update From Breast Cancer Program

Recent clinical efficacy results from the BRACELET-1 trial in HR+/HER2- breast cancer pave the way for a clinical study designed to support an accelerated approval Key milestones in gastrointestinal cancer clinical trials expected in 2025, with potential for new registration-enabling studies SAN DIEGO and CALGARY, AB , Oct. 4, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, is issuing a corporate update to provide investors with a deeper understanding of recent data and what is expected for 2025.  "We're excited by the recent BRACELET-1 results, which exceeded our expectations and substantiate the strong efficacy signal previously observed in breast cancer patients treated with pelareorep," said Wayne Pisano, Interim CEO and Chair of Oncolytics' Board of Directors.

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study Together, these two studies support the compelling potential of pelareorep-based combination therapy to benefit patients with advanced or metastatic HR+/HER2- breast cancer Oncolytics Biotech is moving forward to secure funding for a registration-enabling study of pelareorep-based therapy in advanced or metastatic breast cancer Over half of BRACELET-1 patients in the pelareorep + chemotherapy arm alive at study end Median OS in the pelareorep + chemotherapy arm not reached; median OS at least 32 months (estimated) vs 18 months for the control chemotherapy-only arm SAN DIEGO and CALGARY, AB , Sept. 19, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced positive clinical results from BRACELET-1, its randomized Phase 2 study evaluating pelareorep in patients with HR+/HER2- advanced or metastatic breast cancer.

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

SAN DIEGO and CALGARY, AB , Sept. 6, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Financial Officer Kirk Look will participate in a fireside chat at the H.C.

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

SAN DIEGO and CALGARY, AB , Aug. 2, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Medical Officer Dr. Thomas Heineman will participate in a fireside chat at Canaccord Genuity's 44th Annual Growth Conference, which is taking place August 13-15, 2024 at the InterContinental Boston Hotel in Boston, MA. Additional details on the fireside chat can be found below.

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference

Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q2 2024 Results Conference Call August 1, 2024 4:30 PM ET Company Participants Jon Patton - Director of Investor Relations and Communication Wayne Pisano - Chair of Oncolytics' Board of Directors, and Interim CEO Tom Heineman - Chief Medical Officer Christophe Degois - Vice President Business Development Kirk Look - Chief Financial Officer Conference Call Participants John Newman - Canaccord Soumit Roy - Jones Research Michael Okunewitch - Maxim Group Rahul Sarugaser - Raymond James Operator Good afternoon, and welcome to Oncolytics Biotech Second Quarter 2024 Conference Call. All participants are now in a listen-only mode.

Oncolytics Biotech Inc. (ONCY) Q2 2024 Earnings Call Transcript

Received productive feedback from Type C meeting with the FDA for the planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer On track to report overall survival results from randomized BRACELET-1 breast cancer study in H2 2024 Dosed first patient in new GOBLET study pancreatic cancer cohort; supported by funding from PanCAN Entered into collaboration with GCAR for inclusion of pelareorep in adaptive registration-enabling pancreatic cancer trial Cash position of $24.9 million provides runway through key milestones into 2025 Management hosting conference call and webcast today at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , Aug. 1, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced recent operational highlights and financial results for the second quarter ended June 30, 2024.

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights

Conference call and webcast to take place on Thursday, August 1, 2024, at 4:30 p.m. ET SAN DIEGO, Calif.

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report overall survival results from the randomized HR+/HER2- metastatic breast cancer BRACELET-1 trial in H2 2024 SAN DIEGO and CALGARY, AB , June 27, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that the Company received productive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC). The FDA supports progression-free survival as the primary endpoint of the study, with overall survival as a key secondary endpoint.

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

Wayne Pisano, Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast cancer study continues to be expected in H2 2024 Pelareorep combination therapy advancing towards registration-enabling study in pancreatic cancer SAN DIEGO and CALGARY, AB , June 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced that Matt Coffey, PhD, President and Chief Executive Officer of Oncolytics will take a medical leave of absence, effective immediately. Wayne Pisano, Chair of Oncolytics' Board of Directors, will serve as the interim CEO during Dr. Coffey's absence.

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence

Demonstrating pelareorep's synergy with modified FOLFIRINOX +/- atezolizumab in pancreatic cancer could expand the number of patients it may benefit Funding for the study comes from the US$5 million Therapeutic Accelerator Award from PanCAN SAN DIEGO, and CALGARY, AB , June 20, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, announced the dosing of the first patient in the new GOBLET study cohort evaluating pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®) in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The co-primary endpoints of the cohort are objective response rate (ORR) and safety.

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer

Oncolytics Biotech (ONCY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Oncolytics Biotech (ONCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Trial-in-progress abstract highlights new cohort that could expand the company's pancreatic cancer program Pelareorep's ability to expand TILs highlights its immunotherapeutic mechanism of action and potential as a backbone immunotherapy for multiple indications SAN DIEGO and CALGARY, AB , May 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, presented two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. One is a trial-in-progress abstract discussing cohort 5 of the GOBLET study, which will evaluate the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients.

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

SAN DIEGO and CALGARY, AB , May 16, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Wednesday, May 15, 2024. A total of 41.34% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Anticipated evaluation to include combination therapy featuring treatment regimen of checkpoint inhibition and chemotherapy utilized in cohort 1 of the GOBLET study GCAR is launching a new master protocol for pancreatic cancer with the intent to create a registration-enabling pathway for investigational therapies Innovative adaptive design could accelerate registrational study timeline and provide substantial cost savings compared to traditional trial designs SAN DIEGO and CALGARY, AB , May 15, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it has entered into a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR). The purpose of the preliminary collaboration is to commence planning activities for the evaluation of pelareorep in the treatment of first-line metastatic pancreatic ductal adenocarcinoma (PDAC) as part of GCAR's anticipated master protocol for metastatic pancreatic cancer.

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial

Oncolytics Biotech, Inc. (NASDAQ:ONCY ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Jon Patton - Director, Investor Relations and Communication Matthew Coffey - President, CEO & Director Thomas Heineman - Chief Medical Officer, Oncolytics Biotech (U.S.) Kirk Look - CFO Conference Call Participants John Newman - Canaccord Genuity Operator Good afternoon and welcome to Oncolytics Biotech's First Quarter 2024 Conference Call. [Operator Instructions].

Oncolytics Biotech, Inc. (ONCY) Q1 2024 Earnings Call Transcript

Pelareorep advancing to registration-enabling studies Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- metastatic breast cancer Overall survival data from BRACELET-1 breast cancer study expected in H2 2024 Cash position of $29.6 million provides runway through critical milestones into 2025 Management hosting conference call and webcast today at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , May 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced recent operational highlights and financial results for the first quarter ended March 31, 2024.

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study Study of modified FOLFIRINOX/pelareorep/atezolizumab (Tecentriq®) combination expands existing pancreatic cancer program First patient expected to be enrolled in Q2 2024 SAN DIEGO and CALGARY, AB , May 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will commence enrollment into a new GOBLET study pancreatic cancer cohort following both German regulatory and ethics approvals. This cohort will evaluate pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without the PD-L1 immune checkpoint inhibitor atezolizumab (Tecentriq®) in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC).

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

SAN DIEGO and CALGARY, AB , May 8, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference, which is taking place May 14-15, 2024 at the InterContinental New York Barclay in New York, NY. Additional details on the fireside chat can be found below.

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

Conference call and webcast to take place on Thursday, May 9, 2024, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , April 30, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m.

News for Oncolytics Biotech, Inc. Stock (ONCY)